Investigating how a specific protein influences cancer-related inflammation and tumor growth.
Official title: p27pTpT drives cancer-promoting inflammation and shapes the tumor microenvironment (TME) toward a more tumor-permissive state in vivo
Funded at Georgetown University · NIH-10909343 · Data updated 2026-11-12
This study is looking at a protein called p27pTpT in breast cancer to see how it helps cancer cells resist treatment and change their surroundings, with the hope that the findings will lead to new ways to fight the disease and improve care for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | August 17, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $36,274 |
| NIH project number | 5F99CA284295-02 |
| Project ID | NIH-10909343 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with breast cancer, particularly those experiencing treatment resistance.
✕Less likely to help
Patients with non-breast cancers or those who have not undergone any cancer treatment may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called p27pTpT in breast cancer, particularly how it contributes to therapy resistance and alters the tumor microenvironment. By examining the interactions between p27pTpT and other cellular factors, the research aims to uncover mechanisms that allow cancer stem cells to evade treatment and promote tumor growth. The approach includes advanced techniques like ATAC sequencing to analyze gene expression and the tumor environment. Patients may benefit from insights that could lead to new therapeutic strategies targeting these mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that overcome therapy resistance in breast cancer patients.
How similar studies have gone: Previous research has shown promising results in targeting similar molecular mechanisms in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Georgetown University
Washington, United States Active
Researchers
- Principal investigator: Razavipour, Seyedehfatemeh — Georgetown University
- Study coordinator: Razavipour, Seyedehfatemeh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.